Clinical studies recruiting near West Seneca

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · National Cancer Institute (NCI) · NCT05564390 Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · SWOG Cancer Research Network · NCT06769126 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · NRG Oncology · NCT05174169 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Alliance for Clinical Trials in Oncology · NCT06876714 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · National Cancer Institute (NCI) · NCT04269902 E-Mindfulness Approaches for Living After Breast Cancer
Phase 3 · NRG Oncology · NCT06748222 Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely
Phase 3 · NRG Oncology · NCT03180268 Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent
Phase 2 · National Cancer Institute (NCI) · NCT06900595 Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · National Cancer Institute (NCI) · NCT05554393 Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 · SWOG Cancer Research Network · NCT05633615 Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · National Cancer Institute (NCI) · NCT06498635 Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NA · Eastern Cooperative Oncology Group · NCT05108298 Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · NRG Oncology · NCT05327686 Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Phase N/A · Wake Forest University Health Sciences · NCT03998202 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · National Cancer Institute (NCI) · NCT06058377 Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin
Phase 2 · National Cancer Institute (NCI) · NCT06917911 An Internet-based Program to Help Cancer Survivors Manage Pain
NA · Wake Forest University Health Sciences · NCT04462302 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Phase N/A · ECOG-ACRIN Cancer Research Group · NCT04239573 Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · National Cancer Institute (NCI) · NCT05987241 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · National Cancer Institute (NCI) · NCT05564377 Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · SWOG Cancer Research Network · NCT04205968 Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Trea
Phase 2 · National Cancer Institute (NCI) · NCT06317649 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT04423211 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head
Phase 2 · ECOG-ACRIN Cancer Research Group · NCT02734537 Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
Phase 2/Phase 3 · SWOG Cancer Research Network · NCT06616584 S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · SWOG Cancer Research Network · NCT03418961 Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Phase N/A · ECOG-ACRIN Cancer Research Group · NCT06002828 Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NA · Alliance for Clinical Trials in Oncology · NCT07283939 Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · National Cancer Institute (NCI) · NCT07195734 S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic
NA · SWOG Cancer Research Network · NCT03723928

Look up another city

Look up another condition